Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.

H. Kantarjian(The University of Texas MD Anderson Cancer Center), AB Deisseroth(The University of Texas MD Anderson Cancer Center), Dimitrios P. Kontoyiannis(The University of Texas MD Anderson Cancer Center), Elihu H. Estey(University of Washington), Stephen O’Brien(The University of Texas MD Anderson Cancer Center), J Gutterman(The University of Texas MD Anderson Cancer Center), Mary Beth Rios(The University of Texas MD Anderson Cancer Center), Moshe Talpaz(University of Michigan–Ann Arbor), M Keating(The University of Texas MD Anderson Cancer Center), Miloslav Beran(The University of Texas MD Anderson Cancer Center)
Journal of Clinical Oncology
March 1, 1992
10.1200/jco.1992.10.3.398
Cited by 65

Related Papers

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
|Blood|2009|3.4k
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
|Clinical Infectious Diseases|2005|3k
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2016|2.8k
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
|Clinical Infectious Diseases|2019|2.8k